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1  Introduction
Human biomonitoring (HBM) has its roots in the analysis 
of biological samples, aimed at looking for markers of 
pharmaceutical compounds and occupational exposures, 
in an effort to prevent the health effects of exposure to 
substances [1, 2]. Biological monitoring is defined as 
the repeated, controlled measurement of chemical or 
biochemical markers in fluids, tissues or other accessible 
samples from subjects exposed (or exposed in the past, 
or to be exposed) to chemical, physical or biological risk 
factors in the workplace and/or the general environment 
[3,4]. The major goals of many research programs on 
biomonitoring are to develop and validate biomarkers 
that reflect specific exposures, and to predict the risk of 
disease in individuals and in population groups [5]. The 
power of HBM to identify spatial and temporal trends in 
human exposures has successfully provided exposure 
and risk information, in order to inform public health 
decisions and/or initiate policy measures, and to focus 
on the protection of susceptible populations, such as 
children and pregnant mothers [7, 8]. Classical examples 
are the ban of lead from gasoline, recommendations 
to avoid mercury-containing amalgam teeth fillings in 
children, the restriction of phthalate use in plastics and 
many others. Additionally, biomonitoring data could 
be used for screening purposes and prioritization of 
chemicals for further research or regulation [6].
Biomonitoring has many advantages over 
environmental monitoring; for example, biological 
samples reveal integrated effects of repeated exposure. 
Biomonitoring data directly reflect the total body 
burden or biological effects resulting from all routes of 
exposure - inhalation, absorption through the skin, and 
ingestion, including hand-to-mouth transfer in children 
- and interindividual variability in exposure levels, 
metabolism and excretion rates. Such data also reflect 
modifying influences in physiology, bioavailability, 
bioaccumulation and persistency, which can magnify 
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the concentrations of some environmental chemicals 
(e.g. persistent organic pollutants, and metals such 
as lead and cadmium) enough to raise them above 
detection thresholds [1,8,9]. For chemicals that are 
excreted rapidly, cross-sectional biomonitoring data 
reflect recent exposure, while characterization of long-
term exposure patterns at the individual level requires 
repetitive sampling [9]. For a given chemical, HBM can 
identify spatial and time trends, lifestyle contributing 
factors, and specific at-risk groups. Therefore, the 
advantages to the individuals that participate in HBM 
studies include: identification of exposure (measure 
of body burden of a contaminant or its metabolite), 
identification of environmental mutagens/carcinogens, 
and determination of the possible range of individual 
susceptibility by studying genetic polymorphisms and/
or pathways related to the possible injury (or causal) 
agent [10]. 
In summary, HBM of dose and biochemical effects 
has tremendous utility, providing an efficient and 
cost effective means of measuring human exposure 
to chemical substances and providing unequivocal 
evidence that both exposure and uptake have been 
taken place [1,8]. It can also identify new chemical 
exposures, track trends and changes in exposure, 
establish distributions of exposure among the general 
population, identify vulnerable groups and populations 
with higher exposures, and identify environmental 
risks at specific contaminated sites with relatively low 
expenditure [8]. 
Moreover, biomonitoring can demonstrate the 
association between body burden of pollutants and/
or contaminants, and respective health effects in 
epidemiological studies merged with health data and 
also to test research hypotheses. Sustained national 
and international surveillance programs typically 
use well established biomonitoring techniques (e.g. 
biomarkers which are known to reflect exposure 
to the chemical of interest, standardized sampling 
methods and verified analytical techniques) to collect 
information on population exposures to environmental 
hazards that are known to be significant to public health 
[9]. Biomonitoring, however, usually does not reveal 
exposure sources and routes. Therefore, environmental 
monitoring remains crucial for the development of 
targeted policy actions [9].
This paper intends to make an overview about 
Human Biomonitoring, focusing on the use of biomarkers 
as biomonitoring tools, and to describe their utility and 
application in occupational health.
2  Biomarkers 
Biomarkers have been defined by the U.S. National 
Academy of Sciences Committee on Biological Markers 
as an alteration in cellular or biochemical components, 
processes, structure or functions that is measurable in a 
biological system or sample [11], but is not a measure of 
the disease, disorder or condition itself [12]. A biomarker 
can be any substance, structure or process that can 
be monitored in tissues or fluids and that predicts or 
influences health, or assesses the incidence or biological 
behavior of a disease. Ideally, biomarkers should be 
accessible (non-invasive), non-destructive, and easy and 
cheap to measure. Identification of biomarkers that are 
on causal pathways, have a high probability of reflecting 
health or the progression to clinical disease, and have 
the ability to account for all or most of the variation in a 
physiological state or the preponderance of cases of the 
specified clinical outcome have largely remained elusive, 
as one is never quite sure if they fulfill such requirements 
[13,14].  
Biological markers can contribute to quantitative 
risk assessment by helping to: determine the forms of 
dose-time-response relationships; assess the biologically 
effective dose; make interspecies comparisons of effective 
dose, relative potency, and effects; resolve the quantitative 
relationships between human interindividual variability; 
and identify subpopulations that are at enhanced 
risk [13]. Nowadays, most research on biomarkers is 
concerned with markers which will increase our ability 
to identify long-term risks due to toxicant exposure, in 
particular the risk of developing cancer, and identify 
early markers of toxicity in the field of environmental or 
ecotoxicology. Previously, biomarkers have been used to 
identify biological changes due to toxic chemicals and 
in the assessment of environmental health as part of an 
integrated approach. Due to the advances of molecular 
epidemiology, many more biological markers predictive of 
long-term effects will be available in the future, allowing 
risk assessment judgments to be made in a more accurate 
way [15].
The challenge in biomarker research is to facilitate the 
identification of environmental and genetic factors which 
modulate cancer risk; this challenge must be seen in the 
context of the fact that most environmental carcinogens 
appear to be associated with relative risks which are 
so low that they are not easily detected by classical 
epidemiological methods [16]. A goal in the utilization 
of biomarkers must be to identify adverse effects of 
chemical contaminants at the lowest levels of biological 
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organization, so avoiding toxicological problems at higher 
stages [15]. 
Biomarkers (either parent compounds or their 
metabolites) present a time-variable concentration profile 
that is associated with temporal patterns of exposure and 
elimination kinetics [9]. Exceptions are made for chemicals 
that are persistent in environment, bioaccumulate in 
people and/or wildlife, and are toxic (called PBTs).
The traditional, generally accepted classification 
of biomarkers divides them into three main categories 
- biomarkers of exposure, effect, and susceptibility - 
depending on their toxicological significance [4,13,17]. 
A biomarker of exposure is defined as “an exogenous 
substance or its metabolite or the product of an interaction 
between a xenobiotic agent and some target molecule 
or cell that is measured in a compartment within an 
organism” [4,11]. A biomarker of effect is a measurable 
biochemical, structural, functional, behavioral or any 
other kind of alteration in an organism that, according 
to its magnitude, can be associated with established or 
potential health impairment or disease. A sub-class of 
biomarkers of effect is represented by biomarkers of early 
disease (or early biomarkers of disease), i.e. tests which 
are more closely indicative of a subclinical effect or even 
an early, reversible clinical response [4]. A biomarker 
of susceptibility may be defined as an indicator of an 
inherent or acquired ability of an organism to respond 
to the challenge of exposure to a chemical [4]. A further 
discussion of biomarkers of exposure and of effect 
will be provided below. Although the different types of 
biomarkers are considered as separate and alternative 
for classification purposes, it is not always possible to 
attribute them to a single category. The allocation of a 
biomarker to one type or the other sometimes depends on 
its toxicological significance and the specific context in 
which the test is being used [4]. 
With respect to prevention, the use of biomarkers 
to quantify interindividual variability in response to 
exposure has significant implications for carcinogenic 
risk assessment and associated regulatory actions. The 
assumption underlying current risk assessment models 
- that all humans respond homogeneously to a specific 
carcinogen or mixture of carcinogens - is belied by the 
large interindividual variation observed within human 
populations exposed to similar levels of diverse carcinogens. 
2.1  Biomarkers of exposure
Biomarkers of exposure identify and measure chemical 
residues in tissue or body fluids, metabolites of xenobiotic 
compounds, or physiological outcomes that occur as a 
result of exposure [9].
The fundamental role of biomarkers of exposure 
in occupational health practice is to assess exposure 
by all routes and to complement information obtained 
by workplace environmental monitoring. For many 
reasons (such as being more informative, particularly 
at the individual level), biomarkers of exposure are 
frequently used, when available, as a better substitute for 
environmental monitoring [4], often indicating exposures 
to environmental pollutants which are important to public 
health [8]. 
Exposure biomarkers can reflect bioavailability 
and be influenced by numerous parameters such as 
route of exposure, physiological characteristics of the 
receptor, and chemical characteristics of the xenobiotic. 
Exposure biomarkers have the advantage of providing an 
integrated measure of chemical uptake, a consideration 
that is important in the case of agents that exhibit large 
route-dependent differences in absorption [18]. Also, it is 
important to take in account the kinetics of biomarkers 
of interest, since different matrices reflect exposure over 
different time periods [9]. Another valuable application 
of exposure biomarkers is in evaluating the potential of 
intervention strategies. In either case, biomarkers can 
be used as endpoints, permitting a proof of principle to 
be established in advance of long-term interventions 
where precancerous lesions or cancer itself might be the 
outcome [19]. 
Biomarkers of exposure can be divided into markers 
of internal dose and effective dose. The former gives 
an indication of the occurrence and extent of exposure 
of the organism, and thus the likely concentration of 
a parent compound or metabolite at the target site. 
The simplest indicator of internal dose is the blood 
concentration of a chemical agent measured following 
exposure. The effective dose is an indication of the true 
extent of exposure of what is believed to be the target 
molecule, structure or cell. Both markers of internal 
and effective dose are therefore preferable to measuring 
external levels of the compound in question (for example 
in the workplace), as they take into account biological 
variations in absorption, metabolism and distribution 
of the compound between individuals [15,17]. Other 
examples of applications in occupational contexts are 
the recent publications regarding exposure to Aflatoxin 
B1 in several settings [20-23]. The use of an exposure 
biomarker demonstrates that occupational exposure is 
occurring in specific settings, even when exposure to this 
natural toxin is recognized to occur essentially through 
food consumption.
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2.2  Biomarkers of effect
The International Programme on Chemical Safety 
has defined a biomarker of effect as “a measurable 
biochemical, physiological, behavioral or other alteration 
within an organism that, depending upon the magnitude, 
can be recognized as associated with an established 
or possible health impairment or disease”. This is a 
very broad definition. Biomarkers of effect (also known 
as biomarkers of response) can be elicited as a result 
of interaction of the organism with a host of different 
environmental factors (including chemical, physical, 
and biological agents). This definition encompasses 
biomarkers of effect at the level of the whole organism, 
at the level of organ function, at the level of tissue and 
individual cells, and at the subcellular level [24].
Biomarkers of effect, which measure processes 
of genetic damage, are sometimes used to define 
exposures. Because of this, classifications may be made 
in more mechanistic terms, such as reversible (transient) 
genotoxic responses (exposure/dose) and irreversible 
(permanent) genotoxic responses (effect) [25]. Ideally, a 
biomarker of effect should reflect early reversible changes 
in the organism. DNA adducts are better representations 
of penetration of the agent to the target molecules of 
genotoxic concern than protein adducts; however, the 
fact that DNA molecules are repaired (an example of 
reversible genotoxic response) must be considered when 
using DNA adducts as in vivo dosimeters [25]. Effect or 
irreversible genotoxic endpoints require host processing 
of DNA lesions into informational changes in the cell (e.g. 
mutations) and therefore may be relatively insensitive 
when used as dosimeters [25]. 
Historically and in practical terms, these biomarkers 
have been used most widely and routinely. They can be 
grouped into different categories - markers which are 
the result of pathological damage could be considered 
separately from markers which indicate a metabolic 
lesion [17]. 
Other potential uses of biomarkers of effect include 
monitoring of disease progression and prognosis, and as 
adjuncts to other biomarkers in providing refinements in 
epidemiology and risk assessments. Finally, biomarkers 
offer the opportunity to provide scientific confirmation 
of proposed exposure-disease pathways in vivo in human 
populations. Biomarkers of effect may be particularly 
useful for demonstrating the biologic influence of 
preceding susceptibility factors - for instance, genetic 
polymorphisms of xenobiotic-metabolizing enzymes [24]. 
This type of biomarker indicates early biochemical or 
functional alterations including a wide array of biological 
responses, ranging from physiological adaptations 
to disease. They represent a heterogeneous group of 
indicators, and have different applications depending on 
the toxicological significance. Some of them have been 
used for decades as indirect biological signs of exposure 
rather than markers of effect. This is because they are 
well and promptly correlated with the degree of exposure, 
sometimes, but not always, even at levels of exposure 
without any toxicological significance [4]. 
An important group of effect biomarkers are 
genotoxicity biomarkers in workers exposed to mutagens 
or genotoxic carcinogens, which have been developed 
in animals (even in vitro) and are now increasingly 
applied to occupationally exposed populations,. These 
tests, including chromosomal aberrations, micronuclei 
and the more recent comet assay, may be effective in 
distinguishing exposed from non-exposed subjects at 
high exposure. Mainly used as group indicators, they 
are sensitive but not specific, and in some cases are 
difficult to interpret correctly. However, alkaline comet 
assays appear to be promising in distinguishing between 
different mechanisms of DNA damage, such as covalent 
binding versus oxidative stress [4]. 
Some of the simplest biomarkers can be very 
important tools in biomonitoring, as they may indicate 
more subtle or complex changes taking place in response 
to external stressors. Chromosomal abnormalities can 
also be identified in peripheral lymphocytes and may 
act as surrogate biomarkers of changes in other tissues. 
Micronuclei, translocations and sister chromatid 
exchanges, which can be induced by a wide range of 
exposures reflecting cumulative response to a variety of 
environmental factors, are also important biomarkers 
in this field [15,17,27]. Indeed, there are aspects of risk 
assessment that are best accomplished by irreversible 
genotoxic endpoints [25]. 
In summary, effect biomarkers used as early 
predictors of clinical disease can improve occupational 
health risk assessment and contribute to implement new 
effective disease prevention policies in occupational and 
environmental settings, but they must be first validated 
[4].
2.2.1  Biomarkers of genotoxicity
Over the past decades, biomarker-based approaches have 
been applied in the assessment of exposure to genotoxic 
agents and increases of these biomarkers are considered 
early events associated with disease-related changes [28]. 
For surrogate biomarkers to have disease predictability, 
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it must be demonstrated that the measured genotoxic 
events really mimic disease-causing genotoxic events [25]. 
Biomarkers of genotoxicity are considered as 
biomarkers of early carcinogenic effects, and are used 
to measure specific occupational and environmental 
exposures, to predict the risk of disease, or to monitor 
the effectiveness of exposure control procedures to 
genotoxic chemicals [4,9]. Cytogenetic biomarkers are the 
most frequently used endpoint in human biomonitoring 
studies, and are used extensively to assess the impact 
of environmental, occupational and medical factors on 
genomic stability [24,29]. Lymphocytes, in particular, 
are used as a surrogate for the actual target tissues of 
genotoxic carcinogens [24,26] because of the reasons 
mentioned above.
Genotoxicity biomonitoring endpoints such 
as micronuclei, chromosomal aberrations, and 
8-hydroxydeoxyguanosine (8-OHdG) and DNA repair 
measured by comet assay are the most commonly 
used biomarkers in studies evaluating environmental 
or occupational risks associated with exposure to 
potential genotoxins. A review by Knudsen and Hansen 
[30] on the application of biomarkers of intermediate 
endpoints in environmental and occupational health 
concluded that micronuclei in lymphocytes provided a 
promising approach to assess health risks, but the use 
of chromosomal aberrations is likely to be limited by 
laborious and sensitive procedure of the test and the lack 
of trained cytogeneticists. Nevertheless, methodologies 
like comet assays on peripheral blood lymphocytes, urine 
and tissues are increasingly being used as markers of 
oxidative DNA damage [29,31]. 
2.3   Biomarkers of susceptibility
Biomarkers of susceptibility reflect intrinsic characteristics 
of an organism that make it more susceptible to the 
adverse effects of an exposure to a specific substance 
[9] - namely a chemical, physical or biological agent. A 
biomarker of susceptibility is defined as an indicator or a 
measure of an inherent or acquired ability of an organism 
to respond to the challenge of exposure to a specific 
xenobiotic substance [15,24]. Thus any variation in the 
response of an individual to identical exposures may 
represent some difference in susceptibility, due either to 
the genetic make-up of the individual or to variables and 
environmental influences, such as diet or the uptake and 
absorption of the xenobiotics [15]. 
Biomarkers of susceptibility are concerned with 
factors in kinetics and dynamics of uptake and metabolism 
of exogenous chemicals. Thus the concept encompasses 
enzymes of activation and detoxification, repair enzymes, 
and changes in target molecules for toxic chemicals [24, 
32]. 
Toxicological research in experimental animals and 
humans over many years has revealed that individuals can 
often differ markedly in their qualitative and quantitative 
responses to chemical exposure. Such interindividual 
differences can be genetically mediated, or can be the 
result of some environmental stressor, disease process 
or other epigenetic factor. While these interindividual 
differences can complicate safety evaluation and risk 
assessment activities, they can also be usefully employed 
as biomarkers of individual susceptibility to xenobiotics 
[18].  
Hyper-susceptibility can be defined as a lack of 
capacity, beyond the limits of human variability, to 
tolerate or respond effectively to exogenous toxicants 
or pathogens. The concept of individual variability is 
intrinsic to the interpretation of chemical biomonitoring 
data, as well as to that of any biological or clinical test. 
There are two mechanisms of susceptibility to chemical 
agents: toxicokinetic and toxicodynamic; biomarkers of 
susceptibility may be of either type. A group of potential 
susceptibility biomarkers, with a toxicokinetic mechanism 
for use in humans exposed to chemicals, is represented by 
the in vivo measurement of the specific drug-metabolizing 
enzymes or enzyme activities involved in the chemicals’ 
activation or detoxification reactions [4]. 
Interindividual variation occurs as a result of different 
genetically-inherited backgrounds, modified by dietary 
and environmental exposure and revealed by genotypic 
and phenotypic variations. Susceptibility markers are 
useful because they can partially explain interindividual 
variation inherent in the general population, and thus 
provide a biological rationale for investigation of inherent 
vulnerability prior to exposure to environmental hazards 
[24]. 
Biomarkers of susceptibility do not represent stages 
along the dose-response mechanistic sequence, but 
instead represent conditions that alter the rate of transition 
between the stages or molecular events. The kinetics of 
transition is often governed by specific enzymes or other 
gene products. Consequently, the determination of relative 
enzyme activities or the presence or absence of other gene 
products are often employed as susceptibility biomarkers. 
Enzymes involved in xenobiotic metabolism can be 
particularly important in the overall mechanism of action 
of xenobiotics, and genetic polymorphisms in metabolic 
enzymatic activity are a common basis for interindividual 
differences in toxicity [18]. 
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An example of xenobiotic metabolizing enzymes 
as susceptibility biomarkers is the cytochrome P450 
enzyme system. This system is responsible for oxidative 
(i.e. Phase I) metabolism of a multitude of xenobiotics 
and endogenous molecules, primarily in the liver but 
also in other bioactivated organs. Another important 
detoxification enzyme system with significant use in 
susceptibility studies is glutathione-S-transferase (GST), 
which catalyzes the conjugation (i.e. Phase II metabolism) 
of cellular thiol glutathione (GSH) with oxidized 
xenobiotics [4,18]. 
In addition to enzymes involved in biotransformation, 
other potential susceptibility biomarkers have been 
explored or proposed in human and animal studies. 
These include DNA repair enzyme activities, nuclear 
and cytoplasmic receptor protein levels, oncogenes and 
corresponding gene products, tumor suppressor genes, 
and humoral and cellular immune system components.
Much expectation has been vested in the development 
of genetic biomarkers, but for environmental and 
occupational fields, the research so far has not led to 
any routinely usable biomarkers. Many known genetic 
traits, such as polymorphisms of drugs metabolism, are 
individually only weakly-associated with disease; many 
probably remain unknown, due to the requirement for 
environmental factors. Especially if the risk of disease 
is associated more with exposure than with genotype, 
limiting exposure is the only feasible approach to 
prevention and benefits all [33]. However, genetic based-
methods cannot easily identify all individuals at risk in a 
hazardous environment, due to a lack of understanding 
of the interaction of compensatory genetic and cellular 
mechanisms and complex environmental influences [24]. 
It is important to note that the study of genetic variations 
(e.g. from interethnic differences) associated with 
hazardous exposures can predict population vulnerability. 
Better knowledge of xenobiotic metabolism and the 
pharmacokinetics of toxin elimination will speed progress 
of this work [24]. Possible consequences of differential 
interindividual and interethnic susceptibilities may 
be related to (i) individual expression of clinical signs 
of chemical toxicity, (ii) biological monitoring data in 
exposed workers, and (iii) interpretation of the results of 
epidemiological or molecular epidemiological studies [4]. 
The use of detailed physiologically-based 
pharmacokinetics (PBPK) models for interpreting 
biomonitoring data also allows for the modelling of 
different sources of interindividual variability of the 
Absorption, Distribution, Metabolism and Excretion 
(ADME) process, such as body weight, age, genetic 
polymorphisms in xenobiotic metabolic pathways, 
excretion and elimination rates and others. The previously 
so-called confounders or uncertainty factors can be at the 
light of these models be treated as analyzable variables 
which reflect variations in the susceptibility within a 
population that is exposed to environmental pollutants 
[9].
There is also growing interest in the use and 
identification of “non-invasive” biomarkers, such as 
ones that can be found in urine, exhaled air or saliva 
[17]. These allow more routine sampling in human 
studies and may overcome ethical issues (for example, 
in screening children), and also increase responsiveness 
and compliance rates [9]. Blood is still the most commonly 
used and preferred biological matrix for many chemicals 
in HBM studies, since it is in continuous contact with the 
whole organism and is in equilibrium with the organs 
and tissues where chemicals are deposited [9, 24, 26]. 
HBM studies can also include analysis of environmental 
pollutants in other matrices, such as hair, nails, deciduous 
teeth, cord blood, breast milk, amniotic fluid, placenta, 
meconium, semen, and sweat [9].
3  Biological monitoring in occupa-
tional context 
Biological monitoring has applications in exposure 
assessment and in occupational health surveillance 
programs. The term “biological monitoring” has come into 
use as a natural adaptation of the term “environmental 
monitoring”, i.e. the periodic measurement of the level 
or concentration of a chemical, physical or biological risk 
factor in the workplace environment, which is traditionally 
used as an indirect measure of human exposure [4]. 
When compared with environmental monitoring, 
biological monitoring provides additional information 
which can contribute for a more accurate occupational 
risk assessment at the individual and/or group level [4]. 
According to Manno et al. [4], biological monitoring 
of workers has three main goals: the first is individual 
or collective exposure assessment; the second is health 
protection; and the ultimate objective is occupational 
health risk assessment. It consists of standardized 
protocols aimed at the periodic detection of early 
(preferably reversible) biological signs, ie biomarkers 
which are indicative, if compared with adequate reference 
values, of an actual or potential condition of exposure, 
effect or susceptibility, possibly resulting in health 
damage or disease. Biomarkers are usually more specific 
and sensitive than most clinical tests, and therefore may 
be more effective for assessing a causal relationship 
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between health impairment and chemical exposure when 
a change is first detected in exposed workers [4,10,34]. 
Additionally, biomonitoring can help to fill the 
gaps and give important information related to baseline 
exposure, or provide effect information needed to 
evaluate future exposure or health data. For instance, 
biomonitoring before and after exposure can establish if 
exposure occurred, and if health monitoring should be 
conducted long-term due to possible health effects arising 
after a long period since exposure happened [35].
Experience in biological monitoring gained in 
occupational settings has often been applied to assess 
(the effects of) human exposure to chemicals in the 
general environment. The use of biological fluids/tissues 
to assess human exposure, effects and/or susceptibility to 
chemicals in the workplace, together with the underlying 
data (e.g. personal exposure and biological monitoring 
measurements), represents a critical component of the 
occupational risk assessment process, which is a rapidly 
advancing science [4]. Insofar as biomonitoring data can 
be related to external exposures, it can provide better 
understanding of the relationship between health risks 
to external exposures, and biomonitoring can show 
exposures above or below the reference dose (RfD) [6]. 
In environmental epidemiological studies, biological 
measures of exposure should be preferred, if available, 
to environmental exposure data, as they are closer to the 
target organ dose and provide greater precision in risk 
estimates and in dose-response relationships [4]. These 
studies should include a combination of environmental, 
biomonitoring, and questionnaire/survey data to assess 
exposures [6]. Moreover, if a substance has a sufficiently 
long half-life, biomonitoring tools can be used to estimate 
cumulative dose after repeated exposures, and can 
help characterize the contribution from all the possible 
exposure routes, such as inhalation and dermal exposure 
[35]. As an example, if a worker has a considerable 
dermal exposure due to an accident, biomonitoring will 
provide detailed information regarding internal exposure 
[35]. These studies provide a direct link between levels 
measured in environmental and biological media and 
health outcomes, allowing for an improved estimation of 
risks [6].
Based on the recognition that certain diseases can be 
caused by exposure to environmental contaminants, the 
movement for the prevention of environmental disease 
has gained broad-based public support for decades, and 
the public and regulatory agencies are demanding more 
reliable information on health risks from environmental 
contaminants [36]. However, we should consider that 
different types of biomarkers provide different information 
and therefore should be used with that in mind. For 
instance, biomarkers of exposure allow us to know the 
body burden related to exposure to a specific chemical, 
whereas biomarkers of effect would be most useful when 
associated with a known health outcome [35].
Overall, biomonitoring tools provide information 
for several actions related to occupational health 
interventions. Some of those are: determining if a specific 
exposure has occurred and if it implies a risk to workers 
health; providing knowledge of exposure by all possible 
exposure routes; realizing if health outcomes can be 
expected from exposure; helping to clarify the results 
from clinical testing in some circumstances; recognizing 
the adequacy of control measures in place; and helping to 
demonstrate the link between an occupational exposure 
and a health effect. Finally, the data obtained with 
biomonitoring tools can support health monitoring and 
surveillance programs, and identify possible trends in 
exposure [35].
There should be a trend to increase emphasis on 
monitoring populations which are known to be exposed 
to hazardous environmental contaminants, and on 
providing reliable health risk evaluations [36]. This 
information can also be used to support regulations 
on environmental protection and/or define limits in 
occupational settings. Two issues are crucial in the 
application of predictive biomarkers to public health 
policies, despite involving environmental and/or 
occupational exposures [9,36]. The first is dealing with 
the meaning of differing levels of predictive biomarkers 
at an individual level. A conservative and traditional 
approach is to consider risk predictions valid only at a 
group level. This interpretation allows us to cut down 
the effect of inter-individual variability and reduces 
variability due to technical parameters [37]. On the other 
hand, variability is a fundamental source of information. 
In addition, differences among individuals should not 
be viewed as a nuisance, but should be seen as useful 
hints in hypothesis generation, and as an enhanced 
potential to apply preventive measures in subsets of high 
risk subjects. The second crucial aspect of predictive 
biomarkers is the issue of validation. A biomarker 
must be validated before it can be used for health risk 
assessments, especially as far as regulatory aspects 
are involved. Despite the fact that characterization of 
valid biomarkers is a leading priority in environmental 
research, defining validity is troublesome. Validity is a 
general concept that refers to a range of characteristics 
of the biomarker, and an impressive amount of literature 
has been published on the concept of biomarker validity 
and the various aspects of the validation process [37]. 
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The International Labour Organization (ILO) has 
recommended that occupational health goals for 
industrial nations focus on the hazards of new technology, 
among which pharma and biopharma products are 
leaders. Their unchecked growth cannot continue without 
a parallel commitment to the health and safety of workers 
encountering these “high tech” hazards. Improving the 
present state of affairs therefore requires: (i) recognizing 
healthcare as a “high-hazard” employment sector; (ii) 
strengthening voluntary safety guidelines to the level 
of enforceable regulation; (iii) conducting “potent” 
inspections; (iv) treating hazardous pharmaceuticals like 
the chemical toxicants they are; and (v) protecting health 
care workers at least as well as workers in other high-
hazard sectors [38]. 
4  Limitations and social, ethical, 
and legal implications
The advantages of biological monitoring are countered 
by some important limitations. One of them is that one 
cannot tell from biological monitoring data what source 
the exposure originated from, e.g. whether the exposure 
was generated by occupational or non-occupational 
sources. In order to keep track of what source is 
investigated, the researcher can use questionnaires to get 
individual information, collect pre-exposure samples to 
establish baseline or background levels, and/or involve 
“non-exposed” controls [4]. Some biomarkers may not be 
sufficiently specific for assessing exposure to a particulate 
chemical; for instance, hippuric acid is not very useful 
as a urinary biomarker of toluene exposure due to high 
background values from diet. Therefore, relating exposure 
biomarkers to external exposure levels is not an easy task, 
and it is even more difficult to establish a relationship 
between exposure biomarkers and biological endpoints 
such as adverse responses or effects [4]. 
Biomonitoring is one of the best, and probably the most 
rapidly growing, tool available today for the prevention 
of health effects resulting from occupational exposure to 
chemicals. Therefore, there is a growing attention towards 
scientific and ethical issues, and social implications that 
must include individual risk estimation, communication of 
epidemiological results, and translation of epidemiologic 
data into clinical or occupational health practice [4]. 
The use of human biological samples implies 
special considerations, namely information consent, 
confidentiality, and follow-up as stated in the Declaration 
of Helsinki (www.wma.net). The collection of samples 
and personal information about health status, used for 
research and/or surveillance, must be preceded by a 
notification of the project to the ethical committee; this 
includes a protocol describing, for example, the risk 
of the persons participating, the information (oral or 
written) given to persons participating and the method 
of obtaining informed consent [5,30] (defined as consent 
that is informed, freely given, explicit, specific and 
documented) [9].
According to the International Code of Ethics, 
biomarkers must be chosen based on scientific criteria, 
namely for their validity and their relevance for protection 
of the health of the worker concerned, with due regard 
to their sensitivity, their specificity and their predictive 
value. Biomarkers should not be used as screening tests 
or for insurance purposes [4,39]. 
Some of the most relevant ethical issues faced by 
those involved in biological monitoring, particularly for 
research purposes, are the following: study planning, 
informed consent, confidentiality, communication and 
susceptibility [4]. The information about exposure and 
susceptibility gained by biological monitoring is personal 
and may predict health impairments. Such information 
may therefore be discriminative and thus sensitive in 
relation to future opportunities in occupational health 
insurance. It is therefore of utmost importance to keep all 
information confidential, with precise guidelines on who 
is allowed to use the information [30]. In straightforward 
routine biomonitoring programs, communication of 
individual results (including their interpretation) to each 
worker and of collective results/interpretation to the 
employer and to the workers’ representatives would be 
sufficient in most cases. 
Finally, it is crucial that a correct interpretation 
of individual or collective biomarker data requires a 
comparison of the results with appropriate reference 
values obtained in non-exposed but otherwise comparable 
subjects [4].
The study of susceptibility in human populations 
poses a number of ethical challenges. Special attention 
should be given to the ethical aspects related to the use 
of susceptibility biomarkers; in particular, the benefit to 
the worker in terms of preventive action and the cost in 
terms of their possible removal from the job. In principle, 
biological monitoring should not result in discrimination 
or reduction of job opportunities for the workers involved. 
The recognition of individuals who are subjected 
to a potentially increased risk of cancer from exposure, 
particularly occupational exposure, poses the ethical 
dilemma common to much of the present development 
of biomarker applications: how to prevent susceptible 
individuals from being exposed to these chemicals [24]. 
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Regarding the genetic screening of workers, many critics 
have noted the importance of controlling workplace 
exposures instead of removing susceptible workers 
(“hyper-susceptible”) from the workplace. 
Ethical considerations should always be borne in 
mind before biomonitoring programs are planned and 
implemented, particularly when new or partially validated 
biomarkers are involved. Since the primary purpose of 
biological monitoring is the protection of workers’ health, 
situations must be avoided where the data gathered from 
exposure, effect or susceptibility biomarkers could result 
in an adverse impact on a worker’s status of employment 
and/or quality of life [4]. 
In summary, the strategy for data handling, 
data analysis, interpretation, communication, and 
dissemination of the results to the workers, comparison 
groups, and others involved in the process are all issues 
that should be considered in the beginning of any 
biomonitoring campaign [35].
5  Conclusions
HBM is a scientifically-developed approach for assessing 
human exposures to natural and synthetic compounds 
from the environment, occupation, and lifestyle. In 
order to achieve this, the use of biomarkers represents 
an integrated method of measurement of exposure to a 
given agent (i.e. internal dose), resulting from complex 
pathways of human exposure; it also incorporates 
toxicokinetic information and individual characteristics 
such as genetically-based susceptibility [40].
HBM programs provide essential information for 
identifying chemicals that need to be assessed with regard 
to potential health risks in specific population subgroups 
or areas [9]. It can be an important complement to the 
conventional sources of information for regulatory risk 
assessments and for supporting public and occupational 
health protection policies.
HBM is the only available tool that integrates 
exposures from all sources and provides data for 
epidemiological studies of association strengths, dose 
response relationships, and others. However, it does not 
differentiate the exposure by source [40]. It is important to 
note that HBM alone cannot provide information on how 
long a chemical has been in the body. It should be used 
in conjunction with exposure and health assessments. 
Linking biomonitoring data with dose, exposure, and 
environmental concentrations requires refined modelling 
tools (e.g. PBPK models, probabilistic source-to-dose 
models, and interfaces between exposure and PBPK 
models), advanced statistical approaches, and information 
collection tools to improve the interpretation of linkages 
and to reduce uncertainties [6]. Additional data should 
be collected (e.g., from questionnaires, interviews, etc) to 
provide information about potential sources, namely from 
patterns of dietary habits [40], hobbies and other possible 
confounder factors.
The analysis of HBM data related with environmental 
monitoring and other data of pertinent environmental 
sources, such as lifestyle and diet, can reveal major sources 
and pathways of exposure, identify risk factors and provide 
support to targeted interventions [9]. The implementation 
of standardized approaches to surveillance is mandatory 
to ensure international comparability of human 
biomonitoring data, support for policy actions and 
targeted interventions by identifying populations with 
elevated exposure levels, enabling follow-up monitoring 
to evaluate intervention effectiveness [9]. 
In summary, it is possible to conclude that HBM is 
useful in occupational health intervention, since it allows 
us to obtain detailed information about exposure and 
what can be expected regarding health effects resulting 
from exposure. Therefore, HBM can be considered an 
important tool for preventing exposure and exposure 
outcomes. 
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